Drug Discovery

BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies

BeiGene has entered into an exclusive licence agreement with Singlomics (Beijing DanXu) Biopharmaceuticals for neutralising Covid-19 antibodies.

Engitix signs collaboration and licensing agreement with Takeda to develop anti-fibrotic therapies in advanced liver diseases

Engitix, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement with Takeda Pharmaceutical Company to discover and develop novel therapeutics for advanced fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).

Sinovac signs agreement with Bio Farma Indonesia for Covid-19 vaccine cooperation

Sinovac Biotech, a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Hainan, China with PT Bio Farma, a leading biopharmaceutical company in Indonesia, for the supply, local production and technology licensing in respect of the CoronaVac, Sinovac’s inactivated vaccine candidate against Covid-19.

Acadia buys clinical-stage biotechnology company CerSci Therapeutics

Acadia Pharmaceuticals has added novel pain programme to its portfolio with the acquisition of clinical-stage biotechnology company CerSci Therapeutics.

Bristol Myers Squibb to buy clinical-stage protein engineering firm Forbius

Bristol Myers Squibb (BMS) has signed an agreement to acquire clinical-stage protein engineering company Forbius for an undisclosed sum.

6000TOCi Sensor

Continuous monitoring provides a real-time data advantage over batch or non-continuous methods of total organic carbon (TOC) measurement.

AbCellera acquires OrthoMab bispecific platform from Dualogics

AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics).

J&J to acquire Momenta Pharmaceuticals for $6.5bn

Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Massachusetts-based biotech company focused on immune-mediated diseases, in an all-cash deal worth around $6.5bn.

Europe’s largest initiative launches to accelerate therapy development for Covid-19

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.